Postherpetic Neuralgia Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

(Albany, USA) DelveInsight's "Postherpetic Neuralgia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Postherpetic Neuralgia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Postherpetic Neuralgia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Postherpetic Neuralgia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Postherpetic Neuralgia market.

To Know in detail about the Postherpetic Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postherpetic Neuralgia Market Forecast - https://www.delveinsight.com/report-store/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Postherpetic Neuralgia Market Report:
• The Postherpetic Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, Ono Pharmaceutical Co. Ltd announced a Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia
• In October 2024, JMackem Co., Ltd announced a Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability After Oral Administration of AJH-2947 in Healthy Korean or Caucasian Male Subjects
• In November 2023, Scilex Holding announced the successful completion of a Good Manufacturing Practices (GMP) inspection by the US FDA at Oishi Koseido's (Oishi) enhanced manufacturing facility for ZTlido in Japan. This successful audit enables Scilex to continue commercializing ZTlido, manufactured at a 250 kg scale at Oishi's facility.
• A recent study by Jain et al. (2023) reported that the standardized annual incidence rates of herpes zoster from 2019 to 2021 ranged between 542 and 685 per 100,000 people.
• According to the analysis, there were approximately 2,025,000 incident cases of herpes zoster in the 7MM (seven major markets) in 2022, and this number is expected to increase throughout the study period from 2020 to 2034.
• In 2022, the United States recorded the highest number of incident cases of postherpetic neuralgia (PHN), totaling approximately 281,000 cases. It is anticipated that these cases will continue to rise by the year 2034.
• In the EU4 countries and the UK, Germany reported the highest number of incident cases of postherpetic neuralgia (PHN) in 2022, with approximately 59,000 cases, whereas Spain had the lowest number of incident cases of PHN, around 18,000 cases in the same year.
• Key Postherpetic Neuralgia Companies: Merz Therapeutics GmbH, Lexicon Pharmaceuticals, Merz Therapeutics, Scilex Pharmaceuticals, Daiichi Sankyo, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Key Postherpetic Neuralgia Therapies: IncobotulinumtoxinA, LX9211, XEOMIN (IncobotulinumtoxinA), ZTlido (lidocaine), TARLIGE (mirogabalin besilate), HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, GEn, and others
• The Postherpetic Neuralgia epidemiology based on gender analyzed that Postherpetic Neuralgia is more prominent in females in comparison to males
• The Postherpetic Neuralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postherpetic Neuralgia pipeline products will significantly revolutionize the Postherpetic Neuralgia market dynamics.

Postherpetic Neuralgia Overview
Postherpetic Neuralgia (PHN) is a chronic nerve pain condition that occurs as a complication of shingles, caused by the varicella-zoster virus. PHN develops when nerve fibers are damaged after the shingles rash heals, leading to persistent pain that lasts for months or even years. The most common symptoms include burning, stabbing, or throbbing pain in the area where the shingles outbreak occurred, along with heightened skin sensitivity, itching, and numbness.
The risk of developing Postherpetic Neuralgia increases with age, particularly in individuals over 60, those with weakened immune systems, or those who experience severe shingles outbreaks. Early antiviral treatment for shingles, such as acyclovir or valacyclovir, can reduce the chances of PHN development.
Management of Postherpetic Neuralgia involves medications like gabapentin, pregabalin, and tricyclic antidepressants to control nerve pain. Topical treatments such as lidocaine patches and capsaicin creams provide localized relief. In severe cases, nerve blocks or spinal cord stimulation may be considered.
Preventive measures include the shingles vaccine, which significantly lowers the risk of both shingles and PHN. Early intervention and a multidisciplinary approach are crucial for improving the quality of life for individuals suffering from Postherpetic Neuralgia.

Get a Free sample for the Postherpetic Neuralgia Market Report: https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Postherpetic Neuralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postherpetic Neuralgia Epidemiology Segmentation:
The Postherpetic Neuralgia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of Herpes Zoster in the 7MM
• Total Incident Cases of Postherpetic Neuralgia in the 7MM
• Gender-specific Cases of Postherpetic Neuralgia in the 7MM
• Age-specific Cases of Postherpetic Neuralgia in the 7MM
• Total Treated Cases of Postherpetic Neuralgia in the 7MM

Download the report to understand which factors are driving Postherpetic Neuralgia epidemiology trends @ Postherpetic Neuralgia Epidemiology Forecast - https://www.delveinsight.com/report-store/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Postherpetic Neuralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postherpetic Neuralgia market or expected to get launched during the study period. The analysis covers Postherpetic Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Postherpetic Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postherpetic Neuralgia Therapies and Key Companies
• IncobotulinumtoxinA: Merz Therapeutics GmbH
• LX9211: Lexicon Pharmaceuticals
• XEOMIN (IncobotulinumtoxinA): Merz Therapeutics
• ZTlido (lidocaine): Scilex Pharmaceuticals
• TARLIGE (mirogabalin besilate): Daiichi Sankyo
• HSK16149: Haisco Pharma
• XPF-002: Xenon Pharma
• Civamide Patch: Winston Laboratories
• TV-45070: Teva Branded Pharma
• ATx08-001: Aestus Therapeutics
• KAI-1678: KAI Pharma
• TAK-583: Takeda
• DWP05195: Daewoong Pharma
• Z160: Zalicus
• Retigabine: Bausch Health Americas, Inc.
• Levetiracetam: UCB Pharma
• GEn: XenoPort, Inc.

Scope of the Postherpetic Neuralgia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Postherpetic Neuralgia Companies: Merz Therapeutics GmbH, Lexicon Pharmaceuticals, Merz Therapeutics, Scilex Pharmaceuticals, Daiichi Sankyo, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Key Postherpetic Neuralgia Therapies: IncobotulinumtoxinA, LX9211, XEOMIN (IncobotulinumtoxinA), ZTlido (lidocaine), TARLIGE (mirogabalin besilate), HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, GEn, and others
• Postherpetic Neuralgia Therapeutic Assessment: Postherpetic Neuralgia current marketed and Postherpetic Neuralgia emerging therapies
• Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia market drivers and Postherpetic Neuralgia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Postherpetic Neuralgia Unmet Needs, KOL's views, Analyst's views, Postherpetic Neuralgia Market Access and Reimbursement

To know more about Postherpetic Neuralgia companies working in the treatment market, visit @ Postherpetic Neuralgia Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Postherpetic Neuralgia Market Report Introduction
2. Executive Summary for Postherpetic Neuralgia
3. SWOT analysis of Postherpetic Neuralgia
4. Postherpetic Neuralgia Patient Share (%) Overview at a Glance
5. Postherpetic Neuralgia Market Overview at a Glance
6. Postherpetic Neuralgia Disease Background and Overview
7. Postherpetic Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Postherpetic Neuralgia
9. Postherpetic Neuralgia Current Treatment and Medical Practices
10. Postherpetic Neuralgia Unmet Needs
11. Postherpetic Neuralgia Emerging Therapies
12. Postherpetic Neuralgia Market Outlook
13. Country-Wise Postherpetic Neuralgia Market Analysis (2020-2034)
14. Postherpetic Neuralgia Market Access and Reimbursement of Therapies
15. Postherpetic Neuralgia Market Drivers
16. Postherpetic Neuralgia Market Barriers
17. Postherpetic Neuralgia Appendix
18. Postherpetic Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Acrocallosal Syndrome Market: https://www.delveinsight.com/sample-request/acrocallosal-syndrome-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/myocardial-infarction-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.